MBX Biosciences, Inc. 8-K

What Happened

• MBX Biosciences filed an 8‑K reporting two material events: it entered a lease for new office and laboratory premises and announced a CFO transition.
• On February 24, 2026 MBX signed a lease with 5 Burlington Woods, LLC for approximately 13,642 square feet in Burlington, MA. The Lease Commencement Date is estimated as May 1, 2026, with rent commencing five months after that date. The lease term is four years from the Rent Commencement Date, with a one‑time three‑year extension option. Aggregate base rent is approximately $3.4 million over four years.
• On February 25, 2026 MBX and CFO Richard Bartram entered a separation agreement; Mr. Bartram will remain employed through March 15, 2026 and then serve as a consultant. John Smither will become Interim Chief Financial Officer effective March 16, 2026.

Key Details

• Premises: ~13,642 sq ft in Burlington, MA; estimated lease start May 1, 2026; rent begins five months later.
• Rent: ~ $68,200 per month in the first 12 months (≈ $818,000 for year one); annual increases ≈ 3.0%; total base rent ≈ $3.4 million over 4 years. Additional Rent for pro rata operating expenses, taxes and utilities applies.
• Lease term: 4 years from Rent Commencement Date; one 3‑year extension option; lease not terminable except for breach or bankruptcy.
• CFO transition: Richard Bartram resigns as CFO (effective after March 15, 2026), will consult thereafter; company has begun a search for a new CFO. Interim CFO John Smither’s part‑time employment includes $325,000 annual base salary (pro rata), a target bonus equal to 40% of earned income (pro rated for first year), and a $25,000 sign‑on bonus. Bartram receives transition pay, continued benefits, certain severance protections, a 9‑month post‑consulting extension to exercise vested stock options, and a $13,400 COBRA premium lump sum.

Why It Matters

• The lease is a material real estate commitment that increases MBX’s operating footprint and cash commitments (≈ $3.4M base rent plus shared operating expenses), relevant to liquidity and capital planning.
• The CFO change is material for financial leadership and disclosure: the company has arranged continuity through a consulting transition and an experienced interim CFO (John Smither) while it searches for a permanent replacement.
• Investors should note the timing of cash obligations (rent commencement delayed relative to lease commencement) and the potential short‑term impact on corporate finance resources as the company transitions CFO responsibilities.